Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19TNF in Relapsed IDH-Wildtype Glioma
NCT03779230Phase 2Completed
- Sponsor
- Philogen
- Start
- May 2019
- Primary completion
- Jun 2023
- Modality
- Antibody Fragments, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of onfekafusp alfa in glioblastoma (GBM), sponsored by Philogen. Started May 2019; status: completed.
02
Drugs
onfekafusp alfa
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03779230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03779230.